Victory Capital Management Inc. Has $1.01 Million Stock Position in Orthofix Medical Inc. (NASDAQ:OFIX)

Victory Capital Management Inc. grew its position in Orthofix Medical Inc. (NASDAQ:OFIX) by 3.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 64,807 shares of the medical device company’s stock after buying an additional 2,074 shares during the period. Victory Capital Management Inc. owned 0.17% of Orthofix Medical worth $1,012,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in OFIX. Paradigm Capital Management Inc. NY increased its stake in shares of Orthofix Medical by 31.3% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 2,556,100 shares of the medical device company’s stock valued at $33,894,000 after buying an additional 609,137 shares during the period. Engine Capital Management LP increased its stake in shares of Orthofix Medical by 11.0% in the 2nd quarter. Engine Capital Management LP now owns 3,368,665 shares of the medical device company’s stock valued at $44,668,000 after buying an additional 333,364 shares during the period. Marshall Wace LLP acquired a new stake in shares of Orthofix Medical in the 2nd quarter valued at $2,193,000. AYAL Capital Advisors Ltd grew its stake in shares of Orthofix Medical by 10.2% during the second quarter. AYAL Capital Advisors Ltd now owns 686,794 shares of the medical device company’s stock worth $9,107,000 after purchasing an additional 63,697 shares during the period. Finally, Armistice Capital LLC grew its stake in shares of Orthofix Medical by 1.4% during the second quarter. Armistice Capital LLC now owns 3,750,000 shares of the medical device company’s stock worth $49,725,000 after purchasing an additional 50,000 shares during the period. 89.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Roth Mkm reaffirmed a “buy” rating and set a $22.00 price objective (up from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. Stifel Nicolaus raised Orthofix Medical from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $18.00 to $24.00 in a research note on Friday, November 8th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $23.00.

Orthofix Medical Price Performance

Shares of NASDAQ OFIX opened at $19.13 on Thursday. The business’s 50 day moving average price is $16.74 and its two-hundred day moving average price is $15.73. The company has a market cap of $730.96 million, a PE ratio of -6.18 and a beta of 1.05. The company has a quick ratio of 1.11, a current ratio of 2.39 and a debt-to-equity ratio of 0.25. Orthofix Medical Inc. has a twelve month low of $10.28 and a twelve month high of $20.73.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.